Healthcare / Medical DevicesParis
$1.22
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-2.4M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
N/A
•EV/EBITDA
12.4x
↓ROE
-0.9%
↓Gross Margin
40.9%
↓Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.3%
FCF CAGR
—
FCF margin
-4.8%
FCF / Net income
14.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.0M · net income $-167000.0 · FCF $-2.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.0M | $50.0M | $46.1M | $42.2M | $35.3M |
| Net Income | $-167000.00 | $-167000.00 | $-2.9M | $-4.9M | $-6.8M |
| EBITDA | $3.4M | $3.4M | $702000.00 | $-5.1M | $-3.0M |
| EPS | -0.01 | -0.01 | -0.14 | -0.28 | -0.42 |
| Gross Margin | 40.9% | 40.9% | 39.9% | 37.6% | 39.2% |
| Operating Margin | 2.3% | 2.3% | -2.9% | -21.8% | -14.5% |
| Net Margin | -0.3% | -0.3% | -6.3% | -11.7% | -19.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 1.56 | 1.62 | 0.98 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.4M | $-2.4M | $30000.00 | $-4.4M | $-4.2M |
| Returns | |||||
| ROE | -0.9% | -0.9% | -22.4% | -39.9% | -43.5% |
| Valuation | |||||
| EV/EBITDA | 12.38 | 12.38 | 46.75 | — | — |
| P/B | 1.58 | 1.58 | 1.41 | 1.93 | 1.02 |
| Growth & Yield | |||||
| Revenue Growth | 8.5% | 8.5% | 9.3% | 19.5% | — |
| EPS Growth | 92.9% | 92.9% | 50.0% | 33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.14 → -0.01
Residual
+6.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.